Shamburg News · 8-K filed Nov 12, 2026, 8:01 AM EST

Monopar Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates

MNPR · Monopar Therapeutics

  • Earnings
  • Financial statements
  • Materiality: high

Monopar Therapeutics Inc. issued a press release on November 12, 2026, reporting financial results for the third quarter ended September 30, 2026. The company reported a net loss of $6.2 million, or $0.72 per share, versus a net loss of $3.4 million, or $0.48 per share, in the third quarter of 2025. Cash, cash equivalents and investments were $129.4 million as of September 30, 2026, and the company expects its funds to support operations through at least March 31, 2028.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001437749-26-036385.

Written from the filing by Shamburg Markets. Figures are as reported by the company.